Anika Therapeutics (ANIK) shoots up 7.3% premarket after the firm record a 25% Y/Y increase in Q4 revenue and shows a profit. The company says growth was primarily led by strong domestic and international sales of Orthovisc.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs